---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019449"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:46:54.151675+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Abeona Q1 net loss $31.6M; BLA resubmission expected H2 2024; closed $75M offering

## Summary
- Net loss $31.6M ($1.16/share) vs. $9.1M loss a year ago; cash $62.7M at March 31, up from $52.6M.
- Closed $75M underwritten offering on May 7, 2024; cash runway extended into 2026.
- FDA CRL in April 2024 cited CMC deficiencies; no efficacy/safety issues; BLA resubmission planned H2 2024.
- R&D expense $7.2M (down 10% YoY); G&A expense $7.1M (up 78% YoY).
- Entered $50M credit facility in Jan 2024, drew $20M first tranche.

## SEC filing metadata
- accession: 0001493152-24-019449
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315224019449/0001493152-24-019449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315224019449/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019449
- JSON: https://secwatch.observer/filing/0001493152-24-019449.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019449.txt

## Key facts
- Earnings Releases
  ABEONA THERAPEUTICS INC. reported first quarter of 2024 results: net income Net loss was $31.6 million for the first quarter of 2024, or $1.16 loss per common share, EPS $1.16 loss per common share.
  - Period: first quarter of 2024
  - Net income: Net loss was $31.6 million for the first quarter of 2024, or $1.16 loss per common share
  - EPS: $1.16 loss per common share
  - Result: reported results
  source text: Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/318306/000149315224019449/0001493152-24-019449-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.